Batavia Biosciences and KU Leuven join forces on development of promising COVID-19 vaccine candidate
KU Leuven and Batavia Biosciences today announce their partnership on the development of a vector based COVID-19 vaccine candidate.
To support this activity, KU Leuven has partnered with Batavia Biosciences BV, a frontrunner in developing highly intensified and low-cost vaccine manufacturing processes. Batavia will leverage its vaccine development and manufacturing experience together with its high intensity HIP-Vax® manufacturing technology to develop a clinical manufacturing process for the vaccine candidate, deliver clinical product and prepare for large-scale commercial supply.
Prof Neyts (Head of the Virology research group at the KU Leuven Rega Institute) commented: "RegaVax is the only COVID-19 vaccine candidate based on the yellow fever vaccine. In preclinical models, for example with hamsters, one single dose appears to be highly efficient in protecting against infection with SARS-CoV-2. We hope that this vaccine, will, like the yellow fever vaccine on which it is based, provide, after a single dose, long-lasting protection against this coronavirus."
Dr. Menzo Havenga (CEO, Batavia Biosciences)
The partnership aims to deliver the clinical product and to commence clinical testing in 2021.